HA
BIIB icon

Harfst & Associates’s Biogen BIIB Stock Holding History

Harfst & Associates’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-148
Closed -$40K – 96
2017
Q2 		$40K Hold
148
– – 0.02% 143
2017
Q1 		$40K Buy
+148
New +$41.8K 0.02% 156
2016
Q1 		– Sell
-148
Closed -$45K – 88
2015
Q4 		$45K Hold
148
– – 0.02% 181
2015
Q3 		$43K Sell
148
-56
-27% -$18.5K 0.02% 179
2015
Q2 		$82K Buy
+204
New +$81.9K 0.05% 142

Other funds holding BIIB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Harfst & Associates's BIIB Position: Q3 2017 in Review

Harfst & Associates sold out of Biogen (BIIB) in Q3 2017, closing a stake of 148 shares — an estimated $40K sold.

Harfst & Associates first reported a position in BIIB in Q2 2015 and held it in 5 quarters. The position peaked at $82K in Q2 2015. 1,015 funds tracked by Wall St. Rank hold BIIB as of Q3 2017.

  • Harfst & Associates reported no remaining Biogen position as of Q3 2017 after selling out during the quarter.
  • Harfst & Associates sold 148 Biogen shares in Q3 2017, an estimated $40K.
  • Harfst & Associates first reported a position in Biogen in Q2 2015 and held it in 5 quarters.
  • Harfst & Associates's Biogen position peaked at $82K in Q2 2015.
  • 1,015 funds tracked by Wall St. Rank held Biogen as of Q3 2017.

Based on Harfst & Associates's 13F filing for Q3 2017, filed 7 Nov 2017.